Evofem Biosciences reports Q2 2025 net sales of $4.8mln, improved loss from operations.

• Evofem Biosciences Q2 2025 net sales $4.8mln, up from $4.2mln YoY • Loss from operations improved to $1.3mln, down from $1.4mln YoY • Plans for special meeting to approve A&R merger agreement • Aims to become a wholly-owned subsidiary of Aditxt • Seeks to reduce manufacturing costs by 50% for PHEXXI and SOLOSEC

Evofem Biosciences, Inc. (OTCID: EVFM) has announced its financial results for the second quarter of 2025, demonstrating a rebound in net sales and an improvement in loss from operations compared to the same period last year. The company reported net sales of $4.8 million, a 16% increase from the $4.2 million recorded in the second quarter of 2024 [1].

The company's loss from operations improved to $1.3 million, down from $1.4 million in the prior year quarter. This improvement was driven by a combination of factors, including the addition of SOLOSEC to its product portfolio, an increase in the wholesale average cost (WAC) of PHEXXI, and continued improvements in the gross to net percentage. Total operating expenses for the second quarter of 2025 were $6.1 million, an increase of $0.6 million compared to the prior year period [1].

Evofem also announced plans to advance its merger agreement with Aditxt, Inc. (Nasdaq: ADTX). The company is moving forward with a Special Meeting of Stockholders to approve the A&R Merger Agreement. If approved, Evofem will become a wholly-owned subsidiary of Aditxt [1].

Additionally, Evofem is implementing strategies to reduce manufacturing costs for both PHEXXI and SOLOSEC by approximately 50%. This initiative aims to enhance per-unit profit and facilitate entry into price-sensitive global markets [1].

References:
[1] https://www.marketscreener.com/news/evofem-reports-positive-financial-results-for-second-quarter-of-2025-provides-business-update-ce7c51d9db8df72c